Diagnostic accuracy of the Fibrosis-4 (FIB-4) index for advanced liver fibrosis in Qatari patients with MASLD: Comparison with liver biopsy and FibroScan
Qatar Medical Journal · 2026 · 2026 (2)
DOI: 10.5339/qmj.2026.32 ↗Kurz gefasst
Fachartikel in der Zeitschrift Qatar Medical Journal, 2026. Verfasst von Moataz Derbala und 6 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology, Hamad Medical Corporation, Doha, Qatar. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Metabolically-dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in populations with metabolic risk factors, and the liver fibrosis stage is the main determinant of long-term outcomes. The Fibrosis-4 (FIB-4) index is widely recommended as a first-line noninvasive test for fibrosis risk stratification; however, its diagnostic performance may vary across populations.
Objective
To evaluate the diagnostic performance of the FIB-4 index for detecting advanced liver fibrosis in Qatari residents with MASLD, using liver biopsy as the primary reference standard and FibroScan as a secondary comparator. Methodology : This retrospective, cross-sectional diagnostic accuracy study included adults with MASLD evaluated at Hamad Medical Corporation in Qatar between January 2023 and December 2024. FIB-4 was calculated from routine laboratory parameters, and fibrosis was staged using the METAVIR (Meta-Analysis of Histological Data in Viral Hepatitis) scoring system. It is a histological scoring system used to grade necroinflammatory activity (A0–A3) and stage liver fibrosis (F0–F4). Advanced fibrosis was defined as METAVIR stage ≥F3. Diagnostic performance metrics and the area under the receiver operating characteristic curve (AUROC) were calculated at established cut-offs.
Results
A total of 117 patients were included; 74 patients (63.2%) underwent liver biopsy, and 91 patients (77.7%) underwent FibroScan assessment. Advanced fibrosis was present in 21 patients (17.9%) on biopsy. At a FIB-4 cut-off of 1.3, sensitivity and specificity for detecting advanced fibrosis were 66.7% and 67.9%, respectively, compared with liver biopsy, with an overall accuracy of 67.6% and a negative predictive value of 83.7%. The AUROC for FIB-4 was 0.76.
Conclusion
FIB-4 can be used as a first-line, accountable screening tool, followed by another confirmatory tool in high-risk patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gastroenterology and Hepatology, Hamad Medical Corporation, Doha, Qatar.
- Theodore Bilharz Research Institute, Warraq Al Hadar, Egypt.
- Weill Cornell Medical College, Ar-Rayyan, Qatar.
- Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar.
- Community and Preventive Medicine Department, Primary Health Care Corporation, Doha, Qatar.
- Faculty of Medicine of Sousse, Sousse University, Sousse, Tunisia.
Zitieren
APA
Derbala, M., Obeidat, I. M., Abualsuod, R., Draidi, M., Selim, N., Maatoug, J., & Elkalamawi, A. (2026). Diagnostic accuracy of the Fibrosis-4 (FIB-4) index for advanced liver fibrosis in Qatari patients with MASLD: Comparison with liver biopsy and FibroScan. Qatar Medical Journal, 2026(2). https://doi.org/10.5339/qmj.2026.32
Vancouver
Derbala M, Obeidat IM, Abualsuod R, Draidi M, Selim N, Maatoug J, et al. Diagnostic accuracy of the Fibrosis-4 (FIB-4) index for advanced liver fibrosis in Qatari patients with MASLD: Comparison with liver biopsy and FibroScan. Qatar Medical Journal. 2026;2026(2). doi:10.5339/qmj.2026.32
BibTeX
@article{Derbala2026,
author = {Derbala, Moataz and Obeidat, Ibrahim M and Abualsuod, Raya and Draidi, Mahmoud and Selim, Nagah and Maatoug, Jihene and Elkalamawi, Alaa},
title = {Diagnostic accuracy of the Fibrosis-4 (FIB-4) index for advanced liver fibrosis in Qatari patients with MASLD: Comparison with liver biopsy and FibroScan},
journal = {Qatar Medical Journal},
year = {2026},
volume = {2026},
number = {2},
doi = {10.5339/qmj.2026.32}
}
EUVIMED